Oxford Biomedica First Half 2023 Earnings: Misses Expectations

Oxford Biomedica (LON:OXB) First Half 2023 Results

Key Financial Results

• Revenue: UK£43.1m (down 33% from 1H 2022).
• Net loss: UK£48.0m (loss widened by 88% from 1H 2022).
• UK£0.50 loss per share (further deteriorated from UK£0.27 loss in 1H 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Oxford Biomedica Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 31%. Earnings per share (EPS) also missed analyst estimates by 75%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's shares are down 2.0% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Oxford Biomedica that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.